ArticleESMO open2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764541 (Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation.International journal of molecular sciences · 2026Review
- Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer.Current oncology (Toronto, Ont.) · 2026Review
- Circulating tumor DNA in neoadjuvant therapy for solid tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant endocrine therapy (NET) is used in hormone receptor (HR)-positive, HER2-negative breast cancer to reduce tumor burden before surgery. However, robust biomarkers to predict benefit from NET are lacking. PATIENTS AND
methodsWe evaluated the potential of circulating tumor DNA (ctDNA) before treatment and the dynamics during NET to guide treatment decisions for patients receiving NET. In this retrospective analysis, ctDNA before and after NET from patients enrolled in the phase II PELOPS trial, was assessed using the tissue-free Guardant Reveal assay.
resultsctDNA was detected at the pre-NET timepoint in 37.5% of patients (18/48) and 13.6% (6/44) of patients following NET. Pre-NET ctDNA detection was associated with higher pathological stage and higher residual cancer burden scores after NET. Patients with persistent ctDNA detected pre-surgery had a higher risk of distant recurrence.
conclusionsTaken together, these results support the potential of ctDNA to predict tumor burden before surgery after NET and provide insights into long-term prognosis. CLINICAL TRIAL NUMBER: ClinicalTrials.gov NCT02764541.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.